Immunogenicity of Biosimilar Therapeutics in Drug Development (Q167968): Difference between revisions

Latest revision as of 21:11, 12 September 2024

Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.

Language	Label	Description	Also known as
English	Immunogenicity of Biosimilar Therapeutics in Drug Development	Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.

0 references

0 references

@@ aliases / en / 0 / aliases / en / 0 @@
-Biosimilars
@@ aliases / en / 1 / aliases / en / 1 @@
-Immunogenicity
@@ aliases / en / 2 / aliases / en / 2 @@
-Bioanalytical Methods
@@ aliases / en / 3 / aliases / en / 3 @@
-Therapeutic Proteins
@@ aliases / en / 4 / aliases / en / 4 @@
-Dried Blood Spots
@@ aliases / en / 5 / aliases / en / 5 @@
-Erythropoietin Antibodies
@@ aliases / en / 6 / aliases / en / 6 @@
-Monoclonal Antibodies
@@ aliases / en / 7 / aliases / en / 7 @@
-Regulatory Guidelines
@@ aliases / en / 8 / aliases / en / 8 @@
-Biopharmaceuticals
@@ aliases / en / 9 / aliases / en / 9 @@
-Clinical Outcomes
@@ description / en / description / en @@
-This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safe
+Investigating the safety and effectiveness of biosimilar drugs, including testing methods and potential side effects.
@@ Property / same as @@
-https://openalex.org/T12255
@@ Property / same as: https://openalex.org/T12255 / rank @@
-Normal rank
@@ Property / OpenAlex ID @@
+T12255
@@ Property / OpenAlex ID: T12255 / rank @@
+Normal rank